Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
How to Trip Rapid Review
Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)
Step 2: press
Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.
Effects of iron repletion on VO2max, endurance, and blood lactate in women. To determine the effects of an 8-wk dietary iron supplementation (100 mg.d-1) on low plasma ferritin concentration (< 20 ng.ml-1) and endurance, 20 active women (19-35 yr) were studied while performing a VO2max test and an endurance test (80% VO2max) on a cycle ergometer. Subjects were randomly placed in an iron supplement (IG) or a placebo group (PG) using a double-blind method. After treatment in the IG, ferritin (...) levels were higher (22.5 +/- 3.4 vs 14.3 +/- 2.2 ng.ml-1; P < 0.05), Hb increased (12.8 +/- 0.4 to 14.1 +/- 0.2 g.dl-1; P < 0.05), and TIBC decreased (366.2 +/- 24.8 to 293.8 +/- 14.0 micrograms.dl-1; P < 0.05). Also after treatment the IG's VO2max was significantly greater (P < 0.05) than the PG value and their postendurance blood lactate decreased (5.03 +/- 0.44 to 3.85 +/- 0.6 mM.l-1; P < 0.05). Endurance time to exhaustion increased 38% (37.28 +/- 5.03 to 51.4 +/- 7.45 min) following iron
and 3 than in Group 2 (P < .01). However, body iron stores, reflected in serumferritin level, was significantly better in Group 1 (P < .01); there was no difference in this respect between Groups 2 and 3.(ABSTRACT TRUNCATED AT 250 WORDS) (...) Comparative bioavailability of ferric polymaltose and ferrous sulphate in iron-deficient blood donors. Absolute iron deficiency is treated by correcting the causative lesion and then, traditionally, administering sufficient amounts of ferrous salt to return the haemoglobin level to normal and replenish body stores. The bioavailability of ferric compounds has been questioned and accordingly their therapeutic role remains controversial. A special problem is posed by regular blood donation, where
Long-term blood cholesterol-lowering effects of a dietary fiber supplement. The study evaluated the blood cholesterol-lowering effects of a dietary supplement of water-soluble fibers (guar gum, pectin) and mostly non-water-soluble fibers (soy fiber, pea fiber, corn bran) in subjects with mild to moderate hypercholesterolemia (LDL cholesterol, 3.37-4.92 mmol/L).After stabilization for 9 weeks on a National Cholesterol Education Program Step 1 Diet, subjects were randomly assigned to receive 20 g (...) ), triglyceride, iron, ferritin, or vitamin A or E levels. Similar effects were seen over the subsequent 36-week noncomparative part of the study.The fiber supplement provided significant and sustained reductions in LDL-C without reducing HDL-C or increasing triglycerides over the 51-week treatment period.
corpuscular volume, serumferritin, and liver enzyme activities were measured.The percentage of subjects reporting gastrointestinal symptoms was higher in the 6-mg Cu group than in the <0.01-mg Cu group (P < 0.02). One hundred ninety-five subjects fulfilled the inclusion criteria for the blood studies. Although a significant relation between copper intake and total gastrointestinal symptoms was observed, no relation was found between copper intake or reported symptoms and copper-load (...) healthy adults in whom acute gastrointestinal symptoms (nausea, vomiting, diarrhea, and abdominal pain) were assessed as responses to copper exposure (<0.01, 2, 4, or 6 mg/L water). Blood markers were measured in 240 participants at the end of the survey. Subjects with anemia, inflammation, or infection were excluded. Serum and erythrocyte copper, peripheral mononuclear cell copper, serum ceruloplasmin, the nonceruloplasmin bound copper fraction, superoxide dismutase activity, hemoglobin, mean
B (30 patients) treated with epoetin-alpha 10,000 UI twice a week and 525 mg ferrous sulphate 3 times a day. Grouping of patients has been randomized. In both groups hemoglobin, hematocrit, reticulocytes, iron values, ferritine, transferrine, and serological values, have been evaluated sequentially before treatment, before surgery, day of operation, 1st, 2nd, 3rd, 7th postoperative days and at discharge.In group A 86% patients needed blood transfusion (26 out of 30); in group B only 3 (...) Elective coronary and valve surgery without blood transfusion in patients treated with recombinant human erythropoietin (epoetin-alpha). This study evaluates the real effectiveness of epoetin-alpha associated with ferrous sulphate, in reducing blood transfusion in patients undergoing elective open heart surgery not treated with autologous donation.Sixty patients had been divided into 2 groups: group A (30 patients) treated with 525 mg ferrous sulphate three time a day per os for 3 weeks; group
was independent of morphologically detected bone marrow disease, MYCN status, and serumferritin level in bivariate Cox analyses.Immunocytologic quantification of neuroblastoma cells in bone marrow and blood at diagnosis and in bone marrow during induction chemotherapy provides prognostic information that can identify patients with very high-risk disease who should be considered for experimental therapy that might improve outcome. (...) Quantitative tumor cell content of bone marrow and blood as a predictor of outcome in stage IV neuroblastoma: a Children's Cancer Group Study. This study investigated the prognostic value of quantifying tumor cells in bone marrow and blood by immunocytology in children with high-risk, metastatic neuroblastoma.Patients with stage IV neuroblastoma (N = 466) registered on Children's Cancer Group study 3891 received five cycles of induction chemotherapy and were randomized either to myeloablative
psychosocial factors, seeking medical attention, menstrual blood loss.Twenty-nine percent of the women had their menstrual blood loss in the normal range (menstrual blood loss <60 mL). By univariate analysis, unemployment, anxiety, perceived inconvenience, abdominal pain, haemoglobin level and serumferritin concentration distinguished this group of women from those with true menorrhagia. Unemployment, perceived inconvenience, abdominal pain and serumferritin remained significant variables by multivariate (...) Psychosocial and other characteristics of women complaining of menorrhagia, with and without actual increased menstrual blood loss. To discover whether psychosocial factors can explain why many women with normal menstrual blood loss seek care for menorrhagia.Cross-sectional comparative study of women referred for menorrhagia.Gynaecology departments of all five university teaching hospitals in Finland.Two hundred and twenty-six women aged 35-49 years complaining of menorrhagia.Several
Effects of iron repletion on blood volume and performance capacity in young athletes. The purpose of this study was to find out whether iron repletion leads to an increase in red blood cell volume (RBV) and performance capacity in iron-deficient nonanemic athletes.40 young elite athletes (13-25 yr) with low serumferritin (< 20 microg.L-1) and normal hemoglobin (males > 13.5 g.dL-1, females > 11.7 g.dL-1) were randomly assigned to 12-wk treatment with either twice a day ferrous iron (equivalent (...) to 2 x 100 mg elemental iron) or with placebo using a double blind method. Before and after treatment, hematological measures and parameters of iron status were determined in venous blood. RBV, blood volume (BV), and plasma volume (PV) were measured by CO rebreathing. For determination of the aerobic and anaerobic capacity (maximal accumulated oxygen deficit, MAOD), the athletes performed an incremental as well as a highly intensive treadmill test.After 12 wk, ferritin levels were within the normal
healthy women with or without menorrhagia were enrolled and randomized to four different Multiload Cu250 intrauterine contraceptive devices, releasing 0 (control), 1.5, 3, or 6 microg of 3-keto-desogestrel daily. Menstrual blood loss, hemoglobin, and serumferritin levels were determined before and during treatment.All 3-keto-desogestrel-copper intrauterine contraceptive devices reduced menstrual blood loss significantly, causing a reduction of up to 30 to 40 mL after 12 months of use. All women (...) with essential menorrhagia were considered to have been successfully treated after 6 months of use. Serumferritin levels rose with all three 3-keto-desogestrel-loaded devices.A Multiload Cu250 intrauterine contraceptive device releasing 1.5 microg of 3-keto-desogestrel daily is able to reduce menstrual blood loss to a very low level and to replete body iron stores in women with or without menorrhagia. Higher doses have no superior effect.
were divided randomly into two groups beginning on day of life 29. Group 1 (n = 24) received red cell transfusions during the 6-week study period, only if certain symptom-based guidelines were met. Group 2 (n = 26) received red cell transfusions to maintain the hematocrit level above 40% for the entire 6 weeks. Infants were monitored for ROP, growth, and associated morbidity. Serial measurements of serum glucose, lactate, ferritin, total iron-binding capacity, and iron were performed.ROP occurred (...) The effect of blood transfusion protocol on retinopathy of prematurity: A prospective, randomized study. Controversy exists regarding the potential influence of anemia and blood transfusions on the rate of retinopathy of prematurity (ROP) in premature infants. A prospective, randomized, masked trial was performed to determine the influence of red blood cell transfusion protocol on ROP incidence and severity in a population of high-risk infants.A total of 50 infants with birth weights <1251 g
in the blood of 18 volunteers upon rEpo administration. Different rEpo regimens, iron, folic acid, and vitamin B12 administration did not significantly modify the percentage increase in hematocrit. However, a significant decrease in circulating ferritin (fr) and an increase in the soluble transferrin receptor (sTfr) were not found in athletes receiving low (30 IU/kg) doses of rEpo. Thus, an increase in the sTfr/fr ratio cannot be used as an indicator of rEpo abuse, at least when the hormone is administered (...) Identification of blood erythroid markers useful in revealing erythropoietin abuse in athletes. Recombinant human erythropoietin (rEpo) is being used with increasing frequency by endurance athletes to improve aerobic potential. Although rEpo administration has been banned by the International Olympic Committee, no methods are available to unequivocally detect its abuse in sports. Prompted by these considerations, we evaluated the main hematological and biochemical modifications measured
Elevation of blood thioredoxin in hemodialysis patients with hepatitis C virus infection. Thioredoxin (TRX) is a stress-inducible thiol-containing protein, which has been shown to be an indicator of oxidative stress in a variety of diseases. The association between oxidative stress and hepatitis C virus (HCV) infection, however, remains unknown in hemodialysis patients.We measured serum TRX levels in 85 hemodialysis patients positive for anti-HCV antibodies (age, 60 +/- 1 years old (...) correlated with time on hemodialysis (r = 0.27, P = 0.01) in HCV-positive patients, while it was associated with the patient's age in HCV-negative patients (r = 0.42, P < 0.01). Blood TRX was significantly correlated with asparate aminotransferase in patients with HCV infection (r = 0.34, P < 0.01) and without HCV infection (r = 0.46, P < 0.01). However, serum TRX was not associated with blood alanine aminotransferase, a relatively specific marker of hepatic cellular damage, in HCV-infected hemodialysis
Haemochromatosis-associated HFE genotypes in English blood donors: age-related frequency and biochemical expression. There are limited data on the frequency and biochemical expression of the haemochromatosis-associated mutations C282Y and H63D in healthy people.We genotyped (bi-directional PCR amplification of specific alleles method) and performed serum iron studies in randomly selected English male blood donors (<4 previous units donated) in four age bands <30, 30-40, 40-50 and >50 years.In (...) 6261 subjects, frequency of C282Y homozygosity (+/+) was 0.3%, C282Y/H63D compound heterozygosity (+/-) 2.0%, and H63D and C282Y heterozygosity +/-, 21.7 and 10.4%, respectively. Genotype distribution was within Hardy-Weinberg equilibrium in each age band. C282Y +/- frequency fell from 11.7% in subjects <30 years to 8.2% in subjects >50 (Chi2 7.19; P<0.005). No such trend was seen for C282Y +/+. In C282Y +/+ subjects, median serumferritin was 247 (range 60-2449) microg/l and exceeded >500 microg/l
. Serum iron, serumferritin and transferrin saturation were also measured.We have found eight (five men and three women) blood donors who are C282Y homozygotes (0.15%) and 74 C282Y/H63D compound heterozygotes (1.38%). Four out of the eight C282Y homozygotes, all men, had high serumferritin and transferrin saturation values. No woman was detected with both iron parameters increased. Only one of the 74 C282Y/H63D compound heterozygotes showed elevated serumferritin and transferrin saturation values (...) Population screening for hemochromatosis: a study in 5370 Spanish blood donors. Hereditary hemochromatosis is associated with homozygosity for C282Y mutation in the HFE gene, elevated serum transferrin saturation and excess iron deposits throughout the body. We conducted a population-based study in Spain to asses the prevalence of the HFE mutations and their effect on iron parameters.We screened 5370 blood donors for the C282Y and H63D HFE mutations by allele-specific polymerase chain reaction
White blood cells as a novel mortality predictor in haemodialysis patients. Many conventional cardiovascular risk factors in the general population are not as predictive in end-stage renal disease (ESRD). As absolute neutrophil count and total white blood cell (WBC) count are associated with adverse cardiovascular outcomes and all-cause mortality, this analysis was undertaken to explore the associations of WBC variables with mortality risk in ESRD.Of a total study population of 44 114 ESRD (...) patients receiving haemodialysis during 1998 at facilities operated by Fresenius Medical Care, North America, 25 661 patients who underwent differential white cell count and had complete follow-up were included. Information on case mix (age, gender, race), clinical (diabetes, body mass index), and laboratory variables (haematocrit, albumin, creatinine, potassium, calcium, phosphorus, bicarbonate, ferritin, transferrin saturation and differential WBC count) was obtained. Associations between lymphocyte
been performed so far on patients with skin phototype VI (Fitzpatrick classification).To study the blood antioxidant status of black patients with active generalized vitiligo.Randox total antioxidant status, selenium, ferritin, transferrin, ceruloplasmin, tocopherol, and retinol levels were evaluated in blood samples obtained from 11 dark-skinned patients from the French West Indies (Isle of Martinique) with recent active lesions of vitiligo and from 11 age- and sex-matched healthy volunteers.Total (...) blood antioxidant status and selenium levels were significantly increased in vitiligo patients, compared to those in sex- and age-matched controls (P < 0.01 and P < 0.02, respectively). Blood levels of ferritin, transferrin, ceruloplasmin, retinol, and tocopherol were not significantly modified.This is the first report on the global blood antioxidant status in vitiligo. The increase in total blood antioxidant status observed in black patients was an unexpected result that needs to be confirmed
Serum transferrin receptors in rheumatoid arthritis. Serum transferrin receptors (sTfR) were determined in patients affected by rheumatoid arthritis (RA) to verify a possible relationship with the degree of anaemia and with the severity of the inflammatory disease.sTfR, IL1-b, TNF-a and common parameters of iron metabolism were studied in 72 patients with active RA. Anaemia (Hb < 12 g/dl) was present in 51 patients. Twenty normal healthy subjects and 40 iron-deficient anaemic patients without (...) chronic inflammatory, infective or malignant diseases were studied as controls.In patients with RA sTfR levels were significantly higher than in the normal group but lower than in iron-deficient anaemic patients and correlated positively with ESR and IL1-b and negatively with Hb. Anaemic patients with RA were divided into two groups. Group A (56%) showed a possible iron deficiency (TSI < 16 and ferritin < 50 ng/ml); group B did not show iron deficiency (TSI > 16 and ferritin > 50 ng/ml
Serum iron concentrations following administration of two different iron preparations. Serum iron curves were determined in two groups of iron deficient patients after oral administration of iron protein succinylate or ferritin. The two preparations induced a significant increase of serum iron from 30 min after administration of a dose corresponding to 80 mg Fe3+. The increase induced by iron protein succinylate was more prolonged than that of ferritin.
. Haemoglobin (Hb) and serum (S-) human placental lactogen (HPL) were measured in all 207 females, while transferrin saturation, S-ferritin and S-erythropoietin (EPO) were measured in 120 females at monthly intervals. Hb: from 27th week of gestation to eight weeks post partum, the placebo treated group had significantly lower Hb levels than the iron treated group (p less than 0.001). Iron status markers: in the placebo group (n = 57), 92% developed exhausted iron stores (i.e. S-ferritin less than or equal (...) Iron supplementation during pregnancy. Effect on iron status markers, serum erythropoietin and human placental lactogen. A placebo controlled study in 207 Danish women. The effect of iron supplementation, 66 mg elemental iron daily, from the 16th week of gestation to delivery, on iron status markers during uncomplicated pregnancies was assessed in a randomised, double-blind, placebo controlled study of 207 healthy women (100 iron treated, 107 placebo treated) and their newborn babies